BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15199491)

  • 1. Congenital and acquired activated protein C resistance.
    Nicolaes GA; Dahlbäck B
    Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
    Dahlbck B
    J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombophilia as a multigenic disease.
    Zöller B; García de Frutos P; Hillarp A; Dahlbäck B
    Haematologica; 1999 Jan; 84(1):59-70. PubMed ID: 10091393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to activated protein C in women using oral contraceptives.
    Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
    Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor V and protein S as cofactors to activated protein C.
    Dahlbäck B
    Haematologica; 1997; 82(1):91-5. PubMed ID: 9107093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early days of APC resistance and FV Leiden.
    Dahlbäck B
    Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of phenotype resistance to activated protein C (APC resistance)].
    Hudecek J; Ivanková J; Dobrotová M; Hybenová J; Pullmann R; Kubisz P
    Vnitr Lek; 1999 Dec; 45(12):723-8. PubMed ID: 10951849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory diagnosis of hereditary thrombophilia.
    Michiels JJ; Hamulyák K
    Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation in blood coagulation factor V associated with resistance to activated protein C.
    Bertina RM; Koeleman BP; Koster T; Rosendaal FR; Dirven RJ; de Ronde H; van der Velden PA; Reitsma PH
    Nature; 1994 May; 369(6475):64-7. PubMed ID: 8164741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
    De Lucia D; De Francesco F; Marotta R; Maisto G; Meo D; Sessa M; Misso M; Galante M; Russo T; Pignalosa O; Napolitano M; Papa ML; Niglio A; Di Micco P
    Exp Oncol; 2005 Jun; 27(2):159-61. PubMed ID: 15995637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [From gene to disease; risk factors for venous thrombosis: factor V Leiden and prothrombin 20210A].
    Reitsma PH; van de Stolpe A
    Ned Tijdschr Geneeskd; 2001 Sep; 145(38):1843-5. PubMed ID: 11593787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraindividual consistency of the activated protein C resistance phenotype.
    Tosetto A; Simioni M; Madeo D; Rodeghiero F
    Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.